The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Open accessAbstract
Background: The albumin levels may potentially be used as a prognostic biomarker in patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close relationship with nutritional and inflammatory status. However, the available data is limited with heterogeneous patient cohorts, sample sizes and variable cut-offs. Therefore, we conducted a systematic review and meta-analysis to evaluate the association between survival outcomes and albumin levels in patients treated with ICIs. Methods: We conducted a systematic review using the PubMed, Web of Science, and Embase databases to filter the published studies up to 1 June 2022. The meta-analyses were performed with the generic inverse-variance method with a random-effects model due to the high degree of heterogeneity. The primary outcome measure was hazard ratio (HR) with 95% confidence intervals (CI). The study protocol was registered with the PROSPERO registry (Registration Number: CRD42022337746). Results: Thirty-six studies encompassing 8406 cancer patients with advanced disease were included in the meta-analyses. Almost half of the studies were conducted in NSCLC cohorts (n = 15), and 3.5 gr/dL was the most frequently used albumin cut-off in the included studies (n = 20). Patients with lower albumin levels had a significantly increased risk of death (HR: 1.65, 95% CI: 1.52–1.80, p < 0.0001) than patients with higher albumin levels. Subgroup analyses for study location, sample size, tumor type and albumin cut-off were demonstrated consistent results. Furthermore, in the subgroup analysis of eight studies using albumin levels as a continuous prognostic factor, every 1 gr/dL decrease in albumin levels was associated with significantly increased risk of death by a factor of 10% (HR: 1.10, 95% CI: 1.05–1.16, p = 0.0002). Similar to analyses with overall survival, the patients with lower albumin levels had an increased risk of progression or death compared to patients with higher albumin levels (HR: 1.76, 95% CI: 1.40–2.21, p < 0.001). Conclusion: The available evidence demonstrates that albumin levels may be a prognostic biomarker in advanced cancer patients treated with ICIs. Further research is needed to delineate the role of albumin levels in patients treated with ICIs in the adjuvant setting, as well as the possible benefit of therapeutic approaches to improve hypoalbuminemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 1×
“Furthermore, tissue-based biomarkers have not been able to reflect the status of the immune system, which is the main driver of ICI efficacy (Havel et al., 2019).”
BackgroundImmune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035 · cited 1×
“Immune checkpoint inhibitors (ICIs) have bocame a vital part of cancer care in the last decade (Darvin et al., 2018; Robert, 2020).”
BackgroundAdjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906 · cited 1×
“, 2022), while ICIs have become standard adjuvant treatment options for melanoma (Eggermont et al., 2018), NSCLC (O’Brien et al.”
BackgroundFuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608 · cited 1×
“Immune checkpoint inhibitors (ICIs) have bocame a vital part of cancer care in the last decade (Darvin et al., 2018; Robert, 2020).”
BackgroundGupta, D., & Lis, C. G. (2010) · Nutrition Journal · doi:10.1186/1475-2891-9-69 · Cited by 1,485 · cited 1×
“While albumin production could be increased in the early stages of exposure to harmful insults like carcinogens, albumin production is significantly decreased in advanced cancer due to malnutrition and the inhibitory pressure of cytokines and chemokines, like C-reactive protein and interleukin-6 on the liver (Gupta an…”
BackgroundHypoalbuminemia: Pathogenesis and Clinical Significance
Soeters, P. B., Wolfe, R. R., & Shenkin, A. (2019) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1451 · Cited by 1,448 · cited 1×
“Similar to peripheral blood-based biomarkers derived from blood count, albumin levels are significantly affected by inflammatory pressure (Soeters et al., 2019), and lower albumin levels are seen in cases of chronic inflammatory disorders and cancer as a negative acute phase reactant (Fiala et al.”
Background
Cited by
IRnet: Immunotherapy response prediction using pathway knowledge-informed graph neural network
Jiang, Y., Immadi, M. S., Wang, D., Zeng, S., On Chan, Y., Zhou, J., Xu, D., & Joshi, T. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.07.036 · Cited by 12
“The research on survival outcomes and prognostic biomarkers for patients treated with ICIs has significantly advanced in recent years [5–8].”
Metadata
- Authors
- Guven, D. C., Sahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., Aksoy, S., & Yalcin, S.
- Venue
- Frontiers in Molecular Biosciences
- Publisher
- Frontiers Media SA
- Published
- 2022-12-02
- Volume
- 9
- Pages
- 1039121-1039121
- ISSN
- 2296-889X (ISSN-L)
- OpenAlex
- W4311116243
- Cited by
- 214
- References
- 18
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fmolb.2022.1039121
- The paper
- Guven, D. C., Sahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., Aksoy, S., & Yalcin, S. (2022). The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Molecular Biosciences. https://doi.org/10.3389/fmolb.2022.1039121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.